Propanc Biopharma, Inc. SEC 10-Q Report
Propanc Biopharma, Inc., a biopharmaceutical company focused on developing new cancer treatments, has released its Form 10-Q report for the quarter ended March 31, 2025. The report provides a detailed overview of the company's financial performance and operational highlights, reflecting its ongoing efforts in cancer treatment development and strategic business initiatives.
Financial Highlights
Revenue: $0 million. The company reported no revenue for the three and nine months ended March 31, 2025, and 2024.
Operating Expenses: $53.13 million for the three months ended March 31, 2025, and $53.63 million for the nine months ended March 31, 2025. The significant increase in operating expenses is primarily due to administration expenses.
Loss from Operations: $(53.13) million for the three months ended March 31, 2025, and $(53.63) million for the nine months ended March 31, 2025. This reflects the absence of revenue and high operating expenses.
Net Loss: $(54.07) million for the three months ended March 31, 2025, and $(54.85) million for the nine months ended March 31, 2025. The net loss increased significantly compared to the prior year due to higher operating expenses.
Net Loss Available to Common Stockholders: $(54.07) million for the three months ended March 31, 2025, and $(54.85) million for the nine months ended March 31, 2025. This reflects the total net loss adjusted for deemed dividends.
Basic and Diluted Net Loss Per Share Available to Common Stockholders: $(12.50) for the three months ended March 31, 2025, and $(38.62) for the nine months ended March 31, 2025. The per-share loss reflects the significant net loss and the increase in shares outstanding.
Business Highlights
Nature of Operations: Propanc Biopharma, Inc. is focused on developing new cancer treatments targeting high-risk patients, particularly cancer survivors, with a follow-up, non-toxic, long-term therapy designed to prevent cancer recurrence and spread. The company is based in Camberwell, Victoria, Australia, and aims to establish global markets for its technologies.
Product Development: The company's lead product candidate, PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development.
Patent Portfolio: As of March 31, 2025, Propanc Biopharma holds 84 granted, allowed, or accepted patents and 6 patents filed or under examination in key global jurisdictions. These patents relate to the use of proenzymes against solid tumors, covering the lead product candidate PRP.
Corporate Structure: The company was originally formed in Melbourne, Victoria, Australia, and has undergone several reorganizations, including the formation of a wholly-owned subsidiary, Propanc (UK) Limited, for submitting an orphan drug application to the European Medicines Agency.
Reverse Stock Split: On August 7, 2024, the company received approval to effectuate a reverse stock split of its common stock at a ratio of one post-split share per sixty thousand pre-split shares, which became effective on January 29, 2025.
Future Outlook: The company plans to capture and protect additional patentable subject matter based on its field of technology relating to pharmaceutical compositions of proenzymes for treating cancer as it advances its lead product candidate, PRP, through various stages of development.
SEC Filing: Propanc Biopharma, Inc. [ PPCB ] - 10-Q - May. 15, 2025